Latest News and Press Releases
Want to stay updated on the latest news?
-
THE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1...
-
Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP New data on spasticity further...
-
SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027 $10 million milestone payment triggered from licensing agreement with Novo Nordisk for LX9851 Zynquista on...
-
Lexicon Pharmaceuticals reported third quarter 2025 financial results and provided an update on key corporate milestones and accomplishments.